Abstract
The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.
| Original language | English |
|---|---|
| Article number | 148 |
| Journal | Journal of Translational Medicine |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - May 10 2019 |
Fingerprint
Keywords
- Adjuvant
- Anti-CTLA-4
- Anti-PD-1
- BRAF inhibitor
- Immunotherapy
- MEK inhibitor
- Melanoma
- Neoadjuvant
- Targeted therapy
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018. / Ascierto, Paolo A.; Bruzzi, Paolo; Eggermont, Alexander; Hamid, Omid; Tawbi, Hussein A.; Van Akkooi, Alexander; Testori, Alessandro; Caracò, Corrado; Puzanov, Igor; Perrone, Francesco.
In: Journal of Translational Medicine, Vol. 17, No. 1, 148, 10.05.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018
AU - Ascierto, Paolo A.
AU - Bruzzi, Paolo
AU - Eggermont, Alexander
AU - Hamid, Omid
AU - Tawbi, Hussein A.
AU - Van Akkooi, Alexander
AU - Testori, Alessandro
AU - Caracò, Corrado
AU - Puzanov, Igor
AU - Perrone, Francesco
PY - 2019/5/10
Y1 - 2019/5/10
N2 - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.
AB - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.
KW - Adjuvant
KW - Anti-CTLA-4
KW - Anti-PD-1
KW - BRAF inhibitor
KW - Immunotherapy
KW - MEK inhibitor
KW - Melanoma
KW - Neoadjuvant
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85065589434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065589434&partnerID=8YFLogxK
U2 - 10.1186/s12967-019-1892-5
DO - 10.1186/s12967-019-1892-5
M3 - Article
VL - 17
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
IS - 1
M1 - 148
ER -